刚刚过去的2024年,大多中国药企的日子并不好过。无论是产业内融资困难与创新内卷的两难境地,还是政策端医疗反腐和集采控费的双重打击,均未有见底信号。产业内翘首以待,上下求索,试图找到新的增量和新的出口。出海仍是标准答案。药智网数据显示,2024年医药领域有近百项出海BD交易,总金额超3500亿元。不过,选择License-out和NewCo的出海企业仍是大多数,通过自主出海证明自己的仍是寥寥。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.